Chronic Disease Interception and GLP-1 Cost Management: Programs That Change the Trajectory

Most cost management strategies in this series reduce this year’s spend. Domestic steering saves on a procedure that already happened. Pharmacy optimization reduces the price of a drug the member is already taking. Maternity management controls the cost of a birth that is already expected. Chronic disease interception and GLP-1 cost management operate on a different timeline. They change what happens next year and the year after. The member whose diabetes remains well managed does not develop nephropathy. The member on a well-structured GLP-1 protocol loses weight, improves cardiovascular markers, and reduces future MSK, cardiovascular, and diabetes claims. The long-term return on investment exceeds the current-year savings because the intervention changes the cost trajectory rather than managing a single event.

Chronic Disease Interception

#

The claims data signals are visible to any TPA that looks for them. Rising hemoglobin A1c, identifiable through lab claims and medication changes, signals deteriorating diabetes control. Increasing blood pressure medication dosages or class changes signal cardiovascular risk escalation. Weight gain correlated with new MSK claims signals the onset of a musculoskeletal cascade. Pharmacy refill gaps signal declining medication adherence, one of the strongest predictors of avoidable complications. A TPA with real-time claims intelligence can identify members on a deteriorating trajectory months before the high-cost complication arrives.

The distinction between managed chronic disease and unmanaged chronic disease is a cost distinction measured in orders of magnitude. A member with well-controlled Type 2 diabetes generates approximately $10,000 to $16,000 in annual medical costs, according to the American Diabetes Association’s 2023 cost analysis. A member whose diabetes progresses to nephropathy, neuropathy, or cardiovascular complications can generate $50,000 to $100,000 or more in a single plan year. A single diabetes-related amputation costs the plan $70,000 to $120,000 in surgical and post-surgical care. These are not theoretical figures for a 25-person level funded plan. A single member crossing the threshold from managed to unmanaged chronic disease can blow through the specific attachment point and trigger stop loss claims that damage the employer’s renewal pricing for years.

Digital chronic disease management vendors have published outcomes data demonstrating that interception works. Omada Health, which serves over 1,600 employers including health plans, health systems, and employers ranging from small businesses to Fortune 500 companies, reported that members in its diabetes program achieved an average 0.8% to 1.4% reduction in hemoglobin A1c, a 15 mg/dL decrease in total cholesterol, and an 11% increase in medication adherence. The company reported cost savings of approximately $1,169 per member per year in its diabetes program, with employer ROI turning positive at six to twelve months and reaching 2.7:1 through year two.

Virta Health, which focuses specifically on Type 2 diabetes reversal through therapeutic carbohydrate restriction, has published peer-reviewed outcomes showing sustained A1c improvements and medication reduction. The vendor market includes Livongo (now part of Teladoc Health), which reported savings of $1,908 per participant per year for diabetes management members, and Omada Health’s hypertension program, which demonstrated clinically meaningful blood pressure reductions alongside its diabetes outcomes.

For a TPA, the operational model is a partnership with one of these vendors, funded through a portion of the claims savings. The TPA identifies eligible members through claims data analysis (members with diabetes, prediabetes, hypertension, or rising-risk indicators), enrolls them in the vendor program, and tracks outcomes over time. The vendor provides digital coaching, connected devices (glucose monitors, blood pressure cuffs, smart scales), structured behavioral interventions, and clinical escalation when needed. The TPA monitors claims-level impact: are the enrolled members’ costs stabilizing or declining relative to matched non-enrolled members?

The interception model is particularly valuable for the level funded populations this series addresses. The 55-to-64 cohort (LFP-06.02) carries the highest chronic disease burden and generates the highest per-member claims. A fractional executive with prediabetes who enrolls in a digital prevention program and avoids progression to diabetes saves the plan $5,000 to $10,000 annually in avoided diabetes-related claims. Multiply that by three or four members across a 25-person plan and the savings justify the entire cost management infrastructure.

GLP-1 Cost Management

#

GLP-1 receptor agonists have become one of the most consequential cost management challenges for employer-sponsored plans. Medications like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza) have demonstrated substantial clinical efficacy for both Type 2 diabetes and weight management. They have also generated extraordinary cost pressure. Injectable GLP-1 medications cost between $8,000 and $16,000 per user per year at list price. USI data shows that adult plan members with Type 2 diabetes who take a GLP-1 cost their employers $21,758 per year on average, compared to $13,961 for members who do not take these drugs: nearly $7,800 more per member per year.

The 2025 Kaiser Family Foundation employer health benefits survey reported that approximately one in five large employers cover GLP-1 drugs when used primarily for weight loss. Sequoia’s 2025 Wellbeing Trends Report found that 26% of companies now cover GLP-1 medications, rising to 40% among employers with more than 500 employees. For level funded plans serving groups of 1 to 50 employees, the cost exposure is acute. A single member on a GLP-1 medication at $12,000 per year represents 3% to 4% of a typical 25-person plan’s claims fund. Two members represent 6% to 8%. Unmanaged GLP-1 utilization can consume the entire savings generated by every other cost management strategy in this series.

The cost management strategy is not exclusion. It is structured access. Self-funded plans are not currently required to cover GLP-1 medications for weight loss under ERISA, although coverage for diabetes remains standard. The plan document is the governing instrument. A TPA that helps employers design a GLP-1 benefit structure that maximizes clinical value while controlling cost serves both the employer’s financial interests and the member’s health interests.

The structured access model has several components. Prior authorization criteria tied to clinical indications: BMI thresholds (typically 30 or above, or 27 with documented comorbidities), confirmed diabetes diagnosis, or documented cardiovascular risk factors. Step therapy requiring first-line treatments before GLP-1 approval: metformin for diabetes, documented lifestyle modification for weight management, evaluation of lower-cost oral medications before injectable GLP-1 approval. The Navitus Health Solutions survey found that more than 70% of respondents supported requirements such as prior authorization, BMI thresholds, or participation in wellness programs before gaining GLP-1 coverage.

Pharmacy channel optimization reduces the per-unit cost. Specialty pharmacy dispensing, mail-order pharmacy for maintenance fills, and manufacturer copay assistance capture all reduce the effective cost to the plan. International pharmacy access (LFP-10.05) offers additional cost reduction for members who qualify. Formulary management through the PBM can include tiered placement, quantity limits, and preferred product selection within the GLP-1 class.

Outcomes tracking is the component most plans lack. A member who has been on semaglutide for six months should show measurable clinical improvement: weight loss, A1c reduction, blood pressure improvement, or cardiovascular biomarker change. If the medication is not producing results, continued coverage is not cost-effective for the plan or clinically appropriate for the member. The TPA that implements outcomes-based continuation criteria, requiring documented clinical response for ongoing coverage, ensures that GLP-1 spending produces actual health improvement rather than indefinite pharmacy expense.

Adherence presents a separate challenge. A Sequoia analysis cited research showing only 14% of GLP-1 users remain on therapy after three years. The stop-start pattern, where members begin medication, discontinue due to cost, side effects, or other factors, and then resume months later, produces the worst possible financial outcome: the plan pays for the medication without receiving the sustained clinical benefit. Wraparound programs that combine medication with behavioral coaching, nutrition support, and lifestyle modification improve adherence and outcomes. Only 14% of employers currently offer third-party wraparound programs alongside GLP-1 coverage, according to Sequoia’s 2025 data.

The Trajectory Change Argument

#

The distinction between managing current-year claims and changing the cost trajectory is the most important analytical frame for evaluating these strategies. A TPA that implements domestic steering saves money on a specific procedure. That saving is real, measurable, and confined to the plan year in which the procedure occurs. A TPA that implements chronic disease interception saves money on complications that would have occurred in future plan years. The member whose diabetes remains controlled at an A1c of 6.8% instead of deteriorating to 9.5% does not generate the nephrology consults, the dialysis claims, the cardiovascular events, or the retinal procedures that uncontrolled diabetes produces. Those avoided claims compound across multiple plan years.

GLP-1 management works on the same trajectory logic but with an additional dimension. A member on a well-managed GLP-1 protocol who loses 15% of body weight reduces future MSK claims (lower joint stress), cardiovascular claims (improved lipid profiles and blood pressure), diabetes claims (improved insulin sensitivity, potential reduction or elimination of diabetes medications), and sleep apnea claims (weight-dependent condition). The downstream claims reduction across multiple categories can exceed the cost of the medication itself, but only if the medication is producing results and the member remains adherent.

The measurement challenge for trajectory-changing strategies is that the savings are partially realized in the current plan year and partially in subsequent years. A member who enrolls in a chronic disease management program in January may show reduced emergency utilization by June (current-year savings) but will show the full impact of avoided complications only in year two and beyond (future-year savings). This creates a value communication challenge for the TPA: the employer who is paying for the program this year may not be the employer who captures the full savings benefit, particularly if the member changes jobs. For the stop loss carrier, the trajectory change reduces future claims exposure, which should improve renewal pricing, but the actuarial models for quantifying avoided future claims in small groups are less developed than the models for quantifying current-year savings.

Implementation and Net Impact

#

Program costs for a 25-person plan break down into two categories. Chronic disease management: vendor fees of approximately $100 to $300 per enrolled member per month, depending on vendor, condition, and program intensity. If four members qualify for enrollment (typical for a 25-person group with average chronic disease prevalence), annual vendor cost is $4,800 to $14,400. Claims analytics infrastructure to identify eligible members and track outcomes: $1,000 to $3,000 annually, often bundled with the TPA’s existing data analytics capability. GLP-1 cost management: prior authorization and step therapy administration costs are generally embedded in the PBM relationship. Outcomes tracking and continuation criteria add administrative cost of approximately $500 to $1,500 annually. Wraparound program (behavioral coaching, nutrition support): $50 to $150 per enrolled member per month for the members on GLP-1 therapy.

Savings estimates require explicit assumptions. For chronic disease interception: if two members out of 25 avoid a significant complication (one avoided diabetes complication at $30,000 to $50,000, one avoided cardiovascular event at $40,000 to $80,000), the gross savings range from $70,000 to $130,000 over a two-year period. Net of implementation cost, the savings remain substantial. For GLP-1 cost management: the savings come from reduced per-unit cost (pharmacy optimization), avoided inappropriate utilization (prior authorization and step therapy), and downstream medical cost reduction for members who respond to treatment. If one member’s GLP-1 pharmacy cost is reduced from $16,000 to $10,000 through channel optimization and international pharmacy access, and one member who does not respond to GLP-1 therapy is transitioned to a lower-cost alternative through outcomes-based continuation criteria, the combined pharmacy savings are $10,000 to $15,000 annually.

The combined net impact of chronic disease interception and GLP-1 cost management on a 25-person plan is estimated at $10,000 to $30,000 in current-year savings plus $20,000 to $50,000 in avoided future-year claims. The current-year savings alone may not justify the implementation cost on a single small plan. The future-year savings and the book-level impact across the TPA’s entire portfolio are where the strategy produces its return.